Business
HLS Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
HLS Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Confere...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nHLS Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference\nCanada NewsWire\nTORONTO, April 23, 2019\n\n\n\nTORONTO, April 23, 2019 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place Tuesday April 30 – Wednesday May 1, 2019 at the Metro Toronto Convention Centre in downtown Toronto. HLS will present on April 30, 2019, at 1:30 p.m. Eastern Time. The Company's presentation will be webcast at: http://wsw.com/webcast/bloomburton4/hls.v/ \nABOUT BLOOM BURTON HEALTHCARE CONFERENCEThe Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.\nABOUT HLS THERAPEUTICS INC.Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. \n \nSOURCE HLS Therapeutics Inc.\n\n\n\nView original content: http://www.newswire.ca/en/releases/archive/April2019/23/c0790.html\n\n\n\n\nDave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, [email protected]; Gilbert G...